Drugs / NM6603
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07292038 | Dec 2025 → Nov 2026 expected | — | NucMito Pharmaceuticals Co. Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT06046066 | Aug 2023 → Apr 2025 | — | NucMito Pharmaceuticals Co. Ltd. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NM6603 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06046066 ↗ |
| Modality | Small molecule | “investigational small molecule” NCT06046066 ↗ |
| Route | Oral | “administered orally” NCT06046066 ↗ |